Top 5 Medical Stocks For 2019

By Emily Gurnon, Next Avenue Contributor 

When Sol Moran, 63, left her home in Puerto Rico to move to Minneapolis, things initially went well. She enjoyed being closer to her son, who lived in a nearby suburb, and she had a job she enjoyed. Then Moran got hit with a constellation of serious illnesses. She wasn’t able to keep up her work as an interpreter and home health aide and didn’t have the energy to get out of her apartment for anything other than medical visits.

Her world became very small.

“I had given up on life,” Moran said last week. “I was wondering sometimes why I had a phone,” since the only calls she received were about doctors’ appointments.

Credit: Shutterstock

‘A Potent Killer’

Loneliness and social isolation are not merely a source of sadness for many older adults. Studies have shown that isolation increases the risk of mental and physical illnesses. In fact, the health risks of prolonged isolation are equivalent to smoking 15 cigarettes a day, according to the AARP Foundation.

Top 5 Medical Stocks For 2019: Atlantic American Corporation(AAME)

Advisors’ Opinion:

  • [By Joseph Griffin]

    Media headlines about Atlantic American (NASDAQ:AAME) have trended somewhat positive recently, Accern Sentiment Analysis reports. The research group rates the sentiment of media coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Atlantic American earned a coverage optimism score of 0.03 on Accern’s scale. Accern also assigned media headlines about the financial services provider an impact score of 46.9140395368088 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

  • [By Logan Wallace]

    Atlantic American (NASDAQ: AAME) and Swiss Re (OTCMKTS:SSREY) are both finance companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations.

Top 5 Medical Stocks For 2019: Chemung Financial Corp(CHMG)

Advisors’ Opinion:

  • [By Shane Hupp]

    Chemung Financial Corp. (NASDAQ:CHMG) announced a quarterly dividend on Friday, May 18th, Wall Street Journal reports. Investors of record on Monday, June 18th will be given a dividend of 0.26 per share by the bank on Monday, July 2nd. This represents a $1.04 dividend on an annualized basis and a dividend yield of 2.06%. The ex-dividend date of this dividend is Friday, June 15th.

  • [By Logan Wallace]

    Get a free copy of the Zacks research report on Chemung Financial (CHMG)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Top 5 Medical Stocks For 2019: Ducommun Incorporated(DCO)

Advisors’ Opinion:

  • [By Stephan Byrd]

    Astronics (NASDAQ: ATRO) and Ducommun (NYSE:DCO) are both small-cap aerospace companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, profitability, risk, earnings and institutional ownership.

  • [By Ethan Ryder]

    Astronics (NASDAQ: ATRO) and Ducommun (NYSE:DCO) are both small-cap aerospace companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, earnings, profitability, institutional ownership, valuation and analyst recommendations.

  • [By Shane Hupp]

    Ducommun (NYSE:DCO) had its target price lifted by Canaccord Genuity from $36.00 to $38.00 in a report released on Monday morning. They currently have a buy rating on the aerospace company’s stock.

  • [By Stephan Byrd]

    Ducommun (NYSE:DCO) had its price target increased by Canaccord Genuity from $36.00 to $38.00. The firm currently has a buy rating on the stock.

    Fortress Biotech (NASDAQ:FBIO) was given a $11.00 target price by analysts at HC Wainwright. The firm currently has a buy rating on the stock.

Top 5 Medical Stocks For 2019: Gartner, Inc.(IT)

Advisors’ Opinion:

  • [By Ethan Ryder]

    Gartner (NYSE:IT) had its price objective hoisted by Morgan Stanley from $133.00 to $140.00 in a research report sent to investors on Wednesday. The firm currently has a $140.13 rating on the information technology services provider’s stock.

  • [By Logan Wallace]

    Get a free copy of the Zacks research report on Gartner (IT)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Joseph Griffin]

    Gartner (NYSE:IT) was downgraded by analysts at ValuEngine from a buy rating to a hold rating.

    Intra-Cellular Therapies (NASDAQ:ITCI) was downgraded by analysts at ValuEngine from a buy rating to a hold rating.

  • [By Danny Vena]

    It isn’t just investors and analysts bestowing praise on Salesforce, but those that provide the rankings for the industry as well. In fact, Salesforce was recently named a leader in Gartner’s (NYSE:IT) Magic Quadrant for the CRM Customer Engagement Center for the 10th consecutive year running.

  • [By Steve Symington]

    Gartner Inc. (NYSE:IT) announced better-than-expected first-quarter 2018 results on Tuesday, detailing double-digit percentage growth led by strong demand for its market-leading research-and-advisory services. The company also modestly reduced its full-year guidance, but only to reflect the impact of recent divestitures.

  • [By Ethan Ryder]

    Gartner Inc (NYSE:IT) Director Karen E. Dykstra sold 1,800 shares of the firm’s stock in a transaction on Thursday, June 7th. The stock was sold at an average price of $137.24, for a total transaction of $247,032.00. Following the transaction, the director now directly owns 19,235 shares of the company’s stock, valued at approximately $2,639,811.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Top 5 Medical Stocks For 2019: Taseko Mines Limited(TGB)

Advisors’ Opinion:

  • [By Logan Wallace]

    Taseko Mines (NYSEAMERICAN:TGB) (TSE:TKO) has earned a consensus rating of “Buy” from the seven research firms that are currently covering the company, Marketbeat.com reports. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company.

  • [By Shane Hupp]

    Taseko Mines Ltd (NYSEAMERICAN:TGB) (TSE:TKO) – Analysts at National Bank Financial issued their Q2 2018 earnings estimates for shares of Taseko Mines in a research report issued on Thursday, July 12th. National Bank Financial analyst D. Demarco anticipates that the mining company will post earnings per share of $0.01 for the quarter. National Bank Financial has a “Outperform” rating on the stock. National Bank Financial also issued estimates for Taseko Mines’ FY2018 earnings at $0.01 EPS.

Leave a Reply

Your email address will not be published. Required fields are marked *